试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-16
Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder
编号:NCT02075047登记状态:提前终止企业 / 申办者:Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
药物 / 成分:placebo oral capsules、ziprasidone oral capsules
登记的停止原因(原文):Based on recent input from FDA, the pre-specified final analysis will be performed at the current enrollment using a re-estimation of the sample size.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-16
A Randomized Double Blind Controlled Trial Comparing Sugammadex and Neostigmine After Thoracic Anesthesia
编号:NCT02256280登记状态:提前终止企业 / 申办者:Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
药物 / 成分:Sugammadex、Neostigmine
登记的停止原因(原文):Low recruiting rate due to not activation of some collaborator centers
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-16
Suvorexant in Insomnia Co-morbid With Fibromyalgia
编号:NCT02684136登记状态:提前终止企业 / 申办者:Henry Ford Health System
药物 / 成分:suvorexant、placebo
登记的停止原因(原文):reduced ability to recruit sufficient number of patients
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-16
M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
编号:NCT03451773登记状态:提前终止企业 / 申办者:National Cancer Institute (NCI)
药物 / 成分:M7824、Gemcitabine
登记的停止原因(原文):Study was closed after one treatment related death.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-16
Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder
编号:NCT03768726登记状态:提前终止企业 / 申办者:Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
药物 / 成分:Ziprasidone、Placebo
登记的停止原因(原文):Pfizer has decided to perform the pre-specified final analysis at the current enrollment using a re-estimation of the sample size.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-16
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC
编号:NCT03905343登记状态:提前终止企业 / 申办者:Swiss Cancer Institute
药物 / 成分:Ribociclib、Mono-chemotherapy、Endocrine-Therapy
登记的停止原因(原文):Feasibility (low patient accrual and financial reasons)
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-16
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
编号:NCT04579133登记状态:提前终止企业 / 申办者:Latin American Cooperative Oncology Group
药物 / 成分:Olaparib、Durvalumab
登记的停止原因(原文):Not approved
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-15
Delayed Start to Ovarian Stimulation
编号:NCT01614067登记状态:提前终止企业 / 申办者:University of California, San Francisco
药物 / 成分:Ganirelix acetate
登记的停止原因(原文):Slow enrollment resulted in withdraw of funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-15
Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
编号:NCT03532009登记状态:提前终止企业 / 申办者:AstraZeneca
药物 / 成分:Sodium Zirconium Cyclosilicate、Placebo
登记的停止原因(原文):Study stopped early due to the COVID-19 pandemic
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-15
Long Term Safety Study of PRALUENT
编号:NCT03694197登记状态:提前终止企业 / 申办者:Regeneron Pharmaceuticals
药物 / 成分:Praluent
登记的停止原因(原文):The primary objective (to evaluate the long-term safety of Praluent) was adequately evaluated in other studies.
查看官方原始记录 ↗